Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
Adv Drug Deliv Rev. 2024 Apr 14:115306. doi: 10.1016/j.addr.2024.115306. Online ahead of print.ABSTRACTCancer immunotherapy represents a revolutionary strategy, leveraging the patient's immune system to inhibit tumor growth and alleviate the immunosuppressive effects of the tumor microenvironment (TME). The recent emergence of immune checkpoint blockade (ICB) therapies, particularly following the first approval of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors like ipilimumab, has led to significant growth in cancer immunotherapy. The extensive explorations on diverse immune checkpoint antibodies have broa...
Source: Advanced Drug Delivery Reviews - April 16, 2024 Category: Drugs & Pharmacology Authors: Youngjin Choi Su Hyun Seok Hong Yeol Yoon Ju Hee Ryu Ick Chan Kwon Source Type: research
Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
Adv Drug Deliv Rev. 2024 Apr 14:115306. doi: 10.1016/j.addr.2024.115306. Online ahead of print.ABSTRACTCancer immunotherapy represents a revolutionary strategy, leveraging the patient's immune system to inhibit tumor growth and alleviate the immunosuppressive effects of the tumor microenvironment (TME). The recent emergence of immune checkpoint blockade (ICB) therapies, particularly following the first approval of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors like ipilimumab, has led to significant growth in cancer immunotherapy. The extensive explorations on diverse immune checkpoint antibodies have broa...
Source: Advanced Drug Delivery Reviews - April 16, 2024 Category: Drugs & Pharmacology Authors: Youngjin Choi Su Hyun Seok Hong Yeol Yoon Ju Hee Ryu Ick Chan Kwon Source Type: research
Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
Adv Drug Deliv Rev. 2024 Apr 14:115306. doi: 10.1016/j.addr.2024.115306. Online ahead of print.ABSTRACTCancer immunotherapy represents a revolutionary strategy, leveraging the patient's immune system to inhibit tumor growth and alleviate the immunosuppressive effects of the tumor microenvironment (TME). The recent emergence of immune checkpoint blockade (ICB) therapies, particularly following the first approval of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors like ipilimumab, has led to significant growth in cancer immunotherapy. The extensive explorations on diverse immune checkpoint antibodies have broa...
Source: Advanced Drug Delivery Reviews - April 16, 2024 Category: Drugs & Pharmacology Authors: Youngjin Choi Su Hyun Seok Hong Yeol Yoon Ju Hee Ryu Ick Chan Kwon Source Type: research
Efficacy and safety of novel immune checkpoint inhibitor ‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis
ConclusionPD-1/PD-L1 inhibitors-based combinations are associated with significant improvement in both PFS and OS for treatment-na ïve ES-SCLC patients. Benmelstobart plus anlotinib with chemotherapy (CT) yielded better survival benefit versus CT alone or other ICIs + CT with caution for more adverse effects along with the addition of an antiangiogenic agent. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Chuang Yang,
Tiantian Xuan,
Qing Gong,
Xin Dai,
Chengjun Wang,
Rongyu Zhang,
Wen Zhao,
Jian Wang,
Weiming Yue,
Jisheng Li Tags: ORIGINAL ARTICLE Source Type: research
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
ConclusionFor patients with advanced non-selective PD-L1 NSCLC, two effective regimens are Pen + CT and Niv + Bev + CT, which rank first in OS and PFS among all patients. Cam + CT and Tor + CT have advantages for OS in patients with SqNSCLC and Non-sqNSCLC, respectively. Niv + Ipi + CT provided the best OS benefit for patients with an ECOG score of 0, while Pem + CT may be the most effective treatment for patients with an ECOG score of 1. Pem + CT has a better effect on female patients and non-smokers. Sin + CT was found to be the most effective treatment for male patients and the ...
Source: Clinical and Translational Oncology - April 16, 2024 Category: Cancer & Oncology Source Type: research
Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas
Pharmacol Res. 2024 Apr 11:107181. doi: 10.1016/j.phrs.2024.107181. Online ahead of print.ABSTRACTKidney cancers comprise about 3% of all new malignancies in the United States. Renal cell carcinomas (RCCs) are the most common type of renal malignancy making up about 85% of kidney cancer cases. Signs and symptoms of renal cell carcinomas can result from local tumor growth, paraneoplastic syndromes, or distant metastases. The classic triad of presentation with flank pain, hematuria, and a palpable abdominal mass occurs in fewer than 10% of patients. Most diagnoses result from incidental imaging findings (ultrasonography or a...
Source: Cell Research - April 13, 2024 Category: Cytology Authors: Robert Roskoski Source Type: research
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial
This study is registered with ClinicalTrials.gov (NCT02488759) and is now completed.FINDINGS: Between October, 2015, and March, 2020, 193 patients were recruited in the recurrent or metastatic cervical cancer cohort of CheckMate 358, of whom 176 were treated. 19 patients received nivolumab monotherapy, 45 received NIVO3 plus IPI1, and 112 received NIVO1 plus IPI3 (45 in the randomised group and 67 in the expansion group). Median follow-up times were 19·9 months (IQR 8·2-44·8) with nivolumab, 12·6 months (7·8-37·1) with NIVO3 plus IPI1, and 16·7 months (7·2-27·5) with pooled NIVO1 plus IPI3. Objective response rate...
Source: Ann Oncol - April 12, 2024 Category: Cancer & Oncology Authors: Ana Oaknin Kathleen Moore Tim Meyer Jos é López-Picazo González Lot A Devriese Asim Amin Christopher D Lao Valentina Boni William H Sharfman Jong Chul Park Makoto Tahara Suzanne L Topalian Manuel Magallanes Alejandro Molina Alavez Tariq Aziz Khan Cathe Source Type: research
Real ‐world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non‐small cell lung cancer
ConclusionsIn real-world practice, CP demonstrated superior PFS compared with CNI. These findings can inform treatment selection in advanced NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 12, 2024 Category: Cancer & Oncology Authors: Ayami Kaneko,
Nobuaki Kobayashi,
Kenji Miura,
Hiromi Matsumoto,
Kohei Somekawa,
Tomofumi Hirose,
Yukihito Kajita,
Anna Tanaka,
Shuhei Teranishi,
Yu Sairenji,
Hidetoshi Kawashima,
Kentaro Yumoto,
Toshinori Tsukahara,
Nobuhiko Fukuda,
Ryuichi Tags: ORIGINAL ARTICLE Source Type: research
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
In patients with previously treated RAS-mutated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a multicenter open-label phase 1b/2 trial was conducted to define the safety and efficacy of the ME... (Source: BMC Cancer)
Source: BMC Cancer - April 11, 2024 Category: Cancer & Oncology Authors: Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, Mark R. Middleton, Ian Chau, Baha Alkuzweny, Ann Alcasid, Xiaosong Zhang and Eric Van Cutsem Tags: Research Source Type: research
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression
Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death receptor-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibodies, form the standard of care in advanced lung cancer. PD-L1 expression status on tumor (TCs) and immune (ICs) cells, as measured by immunohistochemistry (IHC), is a predictive biomarker of the efficacy of PD-1/PD-L1 blockade therapy [1 –3]. Multiple assays have been developed to evaluate PD-L1 expression in conjunction with a particular therapeutic agent. For advanced non-small cell lung cancer (NSCLC), the FDA has approved four assays as companion diagnostics (CDxs), viz., PD-L1 IHC 2...
Source: Lung Cancer - April 6, 2024 Category: Cancer & Oncology Authors: Jun Miyakoshi, Tatsuya Yoshida, Jumpei Kashima, Masayuki Shirasawa, Masahiro Torasawa, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Noboru Yamamoto, Yasushi Yatabe, Takuji Suzuki Tags: Research Paper Source Type: research
Successful treatment of immune checkpoint inhibitor-related periaortitis
We report a 64-year-old patient with melanoma receiving ipilimumab and nivolumab therapy who presented with a periaortic soft tissue mass around the abdominal aorta on restaging fluorodeoxyglucose positron emission tomography/computed tomography imaging. Clinical, laboratory, and radiologic findings resulted in a diagnosis of immune checkpoint inhibitor-related periaortitis. Periaortitis is a rare disease presenting with fibro-inflammatory tissue around the aorta and may lead to serious complications. Immune checkpoint inhibitors were discontinued, and the patient was treated with glucocorticoids, leading to a complete res...
Source: Swiss Medical Weekly - April 5, 2024 Category: General Medicine Authors: Elias D B ührer Ian L Alberts Lisa Christ Berna C Özdemir Source Type: research
Successful treatment of immune checkpoint inhibitor-related periaortitis
We report a 64-year-old patient with melanoma receiving ipilimumab and nivolumab therapy who presented with a periaortic soft tissue mass around the abdominal aorta on restaging fluorodeoxyglucose positron emission tomography/computed tomography imaging. Clinical, laboratory, and radiologic findings resulted in a diagnosis of immune checkpoint inhibitor-related periaortitis. Periaortitis is a rare disease presenting with fibro-inflammatory tissue around the aorta and may lead to serious complications. Immune checkpoint inhibitors were discontinued, and the patient was treated with glucocorticoids, leading to a complete res...
Source: Swiss Medical Weekly - April 5, 2024 Category: General Medicine Authors: Elias D B ührer Ian L Alberts Lisa Christ Berna C Özdemir Source Type: research
Successful treatment of immune checkpoint inhibitor-related periaortitis
We report a 64-year-old patient with melanoma receiving ipilimumab and nivolumab therapy who presented with a periaortic soft tissue mass around the abdominal aorta on restaging fluorodeoxyglucose positron emission tomography/computed tomography imaging. Clinical, laboratory, and radiologic findings resulted in a diagnosis of immune checkpoint inhibitor-related periaortitis. Periaortitis is a rare disease presenting with fibro-inflammatory tissue around the aorta and may lead to serious complications. Immune checkpoint inhibitors were discontinued, and the patient was treated with glucocorticoids, leading to a complete res...
Source: Swiss Medical Weekly - April 5, 2024 Category: General Medicine Authors: Elias D B ührer Ian L Alberts Lisa Christ Berna C Özdemir Source Type: research
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group
Immunotherapy has revolutionized tumour treatment by harnessing the power of the immune system to fight cancer. Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (ipilimumab and tremelimumab), anti-programmed cell death protein 1 (PD-1) (nivolumab, pembrolizumab, cemiplimab, and dostarlimab), and anti-programmed death-ligand 1 (PD-L1) (atezolizumab, avelumab, and durvalumab) monoclonal antibodies are among the most widely used immunotherapeutic agents for a variety of malignancies [1,2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 3, 2024 Category: Cancer & Oncology Authors: Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, Romano Danesi, Stella D'Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida, Stefania Gori, Giampiero Marino, Rossella Mazzilli, Matteo Monami, Mon Tags: Complications of Treatment Source Type: research
Cancers, Vol. 16, Pages 1409: Clinical Outcome of Nivolumab plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab
This study suggests that nivolumab plus ipilimumab is effective, especially in patients who have received durvalumab for 6 months or more, and tolerable for patients who relapsed after durvalumab following CCRT. (Source: Cancers)
Source: Cancers - April 3, 2024 Category: Cancer & Oncology Authors: Atsuto Mouri Satoshi Watanabe Takaaki Tokito Yoshiaki Nagai Yu Saida Hisao Imai Ou Yamaguchi Kunihiko Kobayashi Kyoichi Kaira Hiroshi Kagamu Tags: Article Source Type: research
